Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest MiMedx Group Inc. Stories

2013-06-26 08:31:27

Editor Note: For more information about this release, please scroll to bottom. NEW YORK, June 26, 2013 /PRNewswire/ -- Today, Wall Street Reports announced new research reports highlighting Stryker Corp. (NYSE: SYK), Techne Corp. (NASDAQ: TECH), Hill-Rom Holdings, Inc. (NYSE: HRC), MiMedx Group, Inc. (NASDAQ: MDXG) and Masimo Corporation (NASDAQ: MASI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings...

2013-06-11 12:29:46

MARIETTA, Ga., June 11, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its receipt of three newly issued patents related to tissue allografts derived from the placenta. The U.S Patent Office has issued to MiMedx® U.S. Patent Number 8,409,626, "Placental Tissue Grafts" with a grant date of April 2, 2013. The U.S....

2013-06-10 12:26:13

MARIETTA, Ga., June 10, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that a randomized controlled trial (RCT) for the Company's EpiFix(R) wound care allograft has been published in the International Wound Journal. Parker H. "Pete" Petit, Chairman and CEO, said, "The results of this clinical trial were...

2013-05-28 12:27:35

KENNESAW, Ga., May 28, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the Jefferies 2013 Global Healthcare Conference in New York. Parker H. "Pete" Petit, Chairman and CEO and Michael J. Senken, Chief Financial Officer, are scheduled to present on June 3, 2013 at 1:30 p.m. Eastern Daylight...

2013-05-20 16:26:07

KENNESAW, Ga., May 20, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has secured a revolving line of credit with Bank of America. The revolving line of credit facility, which is secured by the Company's accounts receivable and inventory, allows MiMedx to borrow up to $3.0 million through May 1, 2014. The...

2013-05-01 08:29:46

KENNESAW, Ga., May 1, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NasdaqCM: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended March 31, 2013. Highlights of First Quarter 2013 Results include: Revenue exceeded forecast for fifth consecutive quarter Revenue more than triples over first quarter of 2012 Fifth consecutive quarter of...

2013-04-22 16:25:39

MiMedx Common Stock to begin trading on NASDAQ under the symbol "MDXG" on April 25, 2013 KENNESAW, Ga., April 22, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its common stock has been approved for listing on The NASDAQ Capital Market under the ticker symbol "MDXG." Trading on NASDAQ is expected to...

2013-04-16 08:29:41

KENNESAW, Ga., April 16, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its results for the first quarter ended March 31, 2013, will be released before the opening of the market on Wednesday, May 1, 2013. MiMedx will host a live broadcast of its first quarter conference call on Wednesday, May 1, 2013 at 10:30 AM...

2013-04-11 12:30:23

KENNESAW, Ga., April 11, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTC: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 1(st) Annual Regen Med Investor Day in New York. Michael J. Senken, Chief Financial Officer and Donald B. Ayers, Vice President, National Strategic Accounts, are scheduled to present on April 17(th) at 5:00 p.m. EDT at...

2013-03-18 08:28:09

KENNESAW, Ga., March 18, 2013 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that MiMedx management has received a number of inquiries regarding trading activity in its shares late last week and the resultant drop in the trading price for the Company's common stock. After investigation, management believes that on...